---
title: "Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Decrease in Short Interest"
description: "Atossa Therapeutics, Inc. (NASDAQ:ATOS) experienced a significant 29.3% decrease in short interest in December, dropping to 8,200,000 shares from 11,600,000 shares in November. The current short-inter"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/223481411.md"
published_at: "2024-12-28T14:22:25.000Z"
---

# Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Decrease in Short Interest

> Atossa Therapeutics, Inc. (NASDAQ:ATOS) experienced a significant 29.3% decrease in short interest in December, dropping to 8,200,000 shares from 11,600,000 shares in November. The current short-interest ratio is 11.6 days based on an average daily volume of 705,500 shares. Analysts have mixed views, with HC Wainwright and Ascendiant Capital maintaining a "buy" rating and a target price of $7.00, while StockNews.com downgraded the stock to "sell." Atossa's stock opened at $0.98, with a market cap of $123.42 million and a P/E ratio of -4.46.

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 8,200,000 shares, a decline of 29.3% from the November 30th total of 11,600,000 shares. Based on an average daily trading volume, of 705,500 shares, the short-interest ratio is presently 11.6 days.

Get **Atossa Therapeutics** alerts:

## Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ATOS shares. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 target price on shares of Atossa Therapeutics in a report on Thursday, December 12th. Ascendiant Capital Markets upped their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a "buy" rating in a report on Monday, December 9th. Finally, StockNews.com downgraded Atossa Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, November 18th.

**Get Our Latest Report on ATOS**

## Atossa Therapeutics Stock Down 7.4 %

Shares of Atossa Therapeutics stock opened at $0.98 on Friday. The firm has a market cap of $123.42 million, a price-to-earnings ratio of -4.46 and a beta of 1.21. Atossa Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.31. The company's 50-day simple moving average is $1.27 and its 200-day simple moving average is $1.31.

## Institutional Trading of Atossa Therapeutics

A number of institutional investors have recently modified their holdings of ATOS. XTX Topco Ltd acquired a new stake in shares of Atossa Therapeutics during the 2nd quarter worth about $29,000. Intech Investment Management LLC purchased a new position in shares of Atossa Therapeutics in the 3rd quarter worth about $29,000. SG Americas Securities LLC grew its stake in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock worth $64,000 after buying an additional 30,037 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Atossa Therapeutics in the third quarter valued at about $75,000. Finally, Rhumbline Advisers acquired a new position in shares of Atossa Therapeutics during the second quarter worth about $161,000. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

## Atossa Therapeutics Company Profile

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

## Recommended Stories

-   Five stocks we like better than Atossa Therapeutics
-   What is a Low P/E Ratio and What Does it Tell Investors?
-   Buffett Takes the Bait; Berkshire Buys More Oxy in December
-   Investing In Automotive Stocks
-   Top 3 ETFs to Hedge Against Inflation in 2025
-   What is the Shanghai Stock Exchange Composite Index?
-   These 3 Chip Stock Kings Are Still Buys for 2025

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

→ 30-year market phenomenon opens up overnight opportunity (From ProsperityPub) (Ad)## Should you invest $1,000 in Atossa Therapeutics right now?

Before you consider Atossa Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.

While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [ATOS.US - Atossa Therapeutics](https://longbridge.com/en/quote/ATOS.US.md)
- [NOV.US - NOV](https://longbridge.com/en/quote/NOV.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Atossa Therapeutics Completes Reverse Stock Split | Atossa Therapeutics Inc. has completed a reverse stock split effective February 2, 2026, to regain compliance with Nasda | [Link](https://longbridge.com/en/news/275612646.md) |
| Atos Expects To Exit 10 More Countries In 2026, CEO Says | Atos SE :CEO SALLE: CUSTOMER CONFIDENCE IS RETURNING SLOWLY, PERHAPS MORE SLOWLY THAN I HAD EXPECTED - MEDIA CALLCEO: ST | [Link](https://longbridge.com/en/news/273188859.md) |
| Atos verlängert Vertrag mit EPZ für IT-Dienstleistungen am niederländischen Kernkraftwerk | Atos SE has announced the extension of its existing contract with EPZ for IT services at the Netherlands' only nuclear p | [Link](https://longbridge.com/en/news/274645750.md) |
| Atos Appoints Olivier Vareilhes as Head of Switzerland | Atos Group has appointed Olivier Vareilhes as the new Head of Switzerland, responsible for strategic development across  | [Link](https://longbridge.com/en/news/274617908.md) |
| Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy \| ATOS Stock News | Atossa Therapeutics has received Orphan Drug Designation from the FDA for (Z)-Endoxifen, aimed at treating Duchenne musc | [Link](https://longbridge.com/en/news/272880712.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
